CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
ATI-1777 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04598269
NCT04598269Phase 2Completed
CompareCT.gov

A Phase 2a, Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis

Aclaris Therapeutics, Inc.·interventional·Posted Oct 22, 2020·Updated Sep 28, 2023

In Brief

A Phase 2 clinical trial evaluating ATI-1777 and Vehicle for Atopic Dermatitis. Completed, enrolled 50 participants across 14 sites.

Detailed Summary

This is a first-in-human, randomized, double-blind, parallel-group, vehicle-controlled study to evaluate the efficacy, safety, tolerability, and PK of ATI-1777 solution following twice-daily applications to target areas of participants with moderate or severe atopic dermatitis (AD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedOct 22, 2020
Enrollment StartSep 30, 2020
Primary CompletionApr 8, 2021
Study CompletionApr 22, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.7 years ago

Interventions

ATI-1777drug

ATI-1777 topical solution 2.0% w/w

Vehicledrug

Vehicle topical solution containing no ATI-1777